A citation-based method for searching scientific literature

Andrew D Spearman, Kevin Sweet, Xiao-Ping Zhou, Jane McLennan, Fergus J Couch, Amanda Ewart Toland. J Clin Oncol 2008
Times Cited: 62







List of co-cited articles
552 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.
Douglas F Easton, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Richard J Wenstrup, Kristina Allen-Brady, Sean V Tavtigian, Alvaro N A Monteiro, Edwin S Iversen, Fergus J Couch,[...]. Am J Hum Genet 2007
309
51

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
542
43

Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Georgia Chenevix-Trench, Sue Healey, Sunil Lakhani, Paul Waring, Margaret Cummings, Ross Brinkworth, Amie M Deffenbaugh, Lynn Anne Burbidge, Dmitry Pruss, Thad Judkins,[...]. Cancer Res 2006
131
41

Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.
David E Goldgar, Douglas F Easton, Amie M Deffenbaugh, Alvaro N A Monteiro, Sean V Tavtigian, Fergus J Couch. Am J Hum Genet 2004
274
37

Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Amanda B Spurdle, Sunil R Lakhani, Sue Healey, Suzanne Parry, Leonard M Da Silva, Ross Brinkworth, John L Hopper, Melissa A Brown, Davit Babikyan, Georgia Chenevix-Trench,[...]. J Clin Oncol 2008
61
34

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
Encarna B Gómez García, Jan C Oosterwijk, Maarten Timmermans, Christi J van Asperen, Frans B L Hogervorst, Nicoline Hoogerbrugge, Rogier Oldenburg, Senno Verhoef, Charlotte J Dommering, Margreet G E M Ausems,[...]. Breast Cancer Res 2009
41
39


Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
A Osorio, R L Milne, E Honrado, A Barroso, O Diez, R Salazar, M de la Hoya, A Vega, J Benítez. Hum Mutat 2007
35
42

A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Noralane M Lindor, Lucia Guidugli, Xianshu Wang, Maxime P Vallée, Alvaro N A Monteiro, Sean Tavtigian, David E Goldgar, Fergus J Couch. Hum Mutat 2012
139
24

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
22

Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.
David E Goldgar, Douglas F Easton, Graham B Byrnes, Amanda B Spurdle, Edwin S Iversen, Marc S Greenblatt. Hum Mutat 2008
131
22

Functional assays for classification of BRCA2 variants of uncertain significance.
Daniel J Farrugia, Mukesh K Agarwal, Vernon S Pankratz, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Linda Wadum, Kiley Johnson, Jennifer Mentlick, Sean V Tavtigian,[...]. Cancer Res 2008
88
22

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Amanda B Spurdle, Sue Healey, Andrew Devereau, Frans B L Hogervorst, Alvaro N A Monteiro, Katherine L Nathanson, Paolo Radice, Dominique Stoppa-Lyonnet, Sean Tavtigian, Barbara Wappenschmidt,[...]. Hum Mutat 2012
181
22

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
20

Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
Kangjian Wu, Shannon R Hinson, Akihiro Ohashi, Daniel Farrugia, Patricia Wendt, Sean V Tavtigian, Amie Deffenbaugh, David Goldgar, Fergus J Couch. Cancer Res 2005
101
17

Assessment of functional effects of unclassified genetic variants.
Fergus J Couch, Lene Juel Rasmussen, Robert Hofstra, Alvaro N A Monteiro, Marc S Greenblatt, Niels de Wind. Hum Mutat 2008
80
16

Characterization of BRCA1 ring finger variants of uncertain significance.
Kevin Sweet, Leigha Senter, Robert Pilarski, Lai Wei, Amanda Ewart Toland. Breast Cancer Res Treat 2010
20
50

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Sunil R Lakhani, Jorge S Reis-Filho, Laura Fulford, Frederique Penault-Llorca, Marc van der Vijver, Suzanne Parry, Timothy Bishop, Javier Benitez, Carmen Rivas, Yves-Jean Bignon,[...]. Clin Cancer Res 2005
444
16

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
16

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
V Abkevich, A Zharkikh, A M Deffenbaugh, D Frank, Y Chen, D Shattuck, M H Skolnick, A Gutin, S V Tavtigian. J Med Genet 2004
124
14

Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
S V Tavtigian, A M Deffenbaugh, L Yin, T Judkins, T Scholl, P B Samollow, D de Silva, A Zharkikh, A Thomas. J Med Genet 2006
473
14

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
625
14

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
580
14

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
824
14

Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
Suhwan Chang, Kajal Biswas, Betty K Martin, Stacey Stauffer, Shyam K Sharan. J Clin Invest 2009
57
15

Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.
Logan C Walker, Phillip J Whiley, Fergus J Couch, Daniel J Farrugia, Sue Healey, Diana M Eccles, Feng Lin, Samantha A Butler, Sheila A Goff, Bryony A Thompson,[...]. Hum Mutat 2010
46
19

A guide for functional analysis of BRCA1 variants of uncertain significance.
Gaël A Millot, Marcelo A Carvalho, Sandrine M Caputo, Maaike P G Vreeswijk, Melissa A Brown, Michelle Webb, Etienne Rouleau, Susan L Neuhausen, Thomas v O Hansen, Alvaro Galli,[...]. Hum Mutat 2012
84
14

Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Marcelo A Carvalho, Sylvia M Marsillac, Rachel Karchin, Siranoush Manoukian, Scott Grist, Ramona F Swaby, Turan P Urmenyi, Edson Rondinelli, Rosane Silva, Luis Gayol,[...]. Cancer Res 2007
91
12


Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.
Sergey G Kuznetsov, Pentao Liu, Shyam K Sharan. Nat Med 2008
91
12

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
12

Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.
Joanna R Morris, Laurent Pangon, Chris Boutell, Toyomasa Katagiri, Nicholas H Keep, Ellen Solomon. Hum Mol Genet 2006
76
11

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
11

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.
Leila Mohammadi, Maaike P Vreeswijk, Rogier Oldenburg, Ans van den Ouweland, Jan C Oosterwijk, Annemarie H van der Hout, Nicoline Hoogerbrugge, Marjolijn Ligtenberg, Margreet G Ausems, Rob B van der Luijt,[...]. BMC Cancer 2009
44
15

A full-likelihood method for the evaluation of causality of sequence variants from family data.
Deborah Thompson, Douglas F Easton, David E Goldgar. Am J Hum Genet 2003
87
11

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
A C Antoniou, A P Cunningham, J Peto, D G Evans, F Lalloo, S A Narod, H A Risch, J E Eyfjord, J L Hopper, M C Southey,[...]. Br J Cancer 2008
299
11

Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.
Derek J R Ransburgh, Natsuko Chiba, Chikashi Ishioka, Amanda Ewart Toland, Jeffrey D Parvin. Cancer Res 2010
82
11

Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Megan S Lee, Ruth Green, Sylvia M Marsillac, Nicolas Coquelle, R Scott Williams, Telford Yeung, Desmond Foo, D Duong Hau, Ben Hui, Alvaro N A Monteiro,[...]. Cancer Res 2010
98
11

Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Bing Xia, Qing Sheng, Koji Nakanishi, Akihiro Ohashi, Jianmin Wu, Nicole Christ, Xinggang Liu, Maria Jasin, Fergus J Couch, David M Livingston. Mol Cell 2006
531
11

Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.
Maxime P Vallée, Tiana C Francy, Megan K Judkins, Davit Babikyan, Fabienne Lesueur, Amanda Gammon, David E Goldgar, Fergus J Couch, Sean V Tavtigian. Hum Mutat 2012
53
13

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
11

Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
Ana Osorio, Miguel de la Hoya, Raquel Rodríguez-López, Angel Martínez-Ramírez, Alicia Cazorla, Juan José Granizo, Manel Esteller, Carmen Rivas, Trinidad Caldés, Javier Benítez. Int J Cancer 2002
85
9

Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families.
Emiliano Honrado, Ana Osorio, Roger L Milne, María F Paz, Lorenzo Melchor, Alberto Cascón, Miguel Urioste, Alicia Cazorla, Orland Díez, Enrique Lerma,[...]. Mod Pathol 2007
42
14

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
9

BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
S S Yuan, S Y Lee, G Chen, M Song, G E Tomlinson, E Y Lee. Cancer Res 1999
324
9

BRCA2 is required for homology-directed repair of chromosomal breaks.
M E Moynahan, A J Pierce, M Jasin. Mol Cell 2001
688
9

Prediction and assessment of splicing alterations: implications for clinical testing.
Amanda B Spurdle, Fergus J Couch, Frans B L Hogervorst, Paolo Radice, Olga M Sinilnikova. Hum Mutat 2008
90
9


The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
S R Lakhani, B A Gusterson, J Jacquemier, J P Sloane, T J Anderson, M J van de Vijver, D Venter, A Freeman, A Antoniou, L McGuffog,[...]. Clin Cancer Res 2000
162
9

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.